The Oncologic Endocrinology fellowship is a one-year program accepting one fellow per year. Our program is the only one in the nation to provide advanced training for the evaluation and treatment of endocrine neoplasias. Fellows will acquire the skills and knowledge base for evaluating and treating patients with these complex endocrine tumors.
Faculty with the Department of Endocrine Neoplasia and Hormonal Disorders evaluate, manage and investigate a wide spectrum of tumors of the thyroid, adrenals, parathyroid, pituitary, pancreas and hereditary endocrine syndromes in both adults and children. The Endocrine Center has well-established collaborative relationships with head and neck surgery, surgical endocrinology, medical oncology, genetics, radiology and pathology. This unique concentration of expertise provides a training experience that will develop future leaders in the field of endocrine neoplasia.
The curriculum includes outpatient and inpatient management of patients with complicated endocrine neoplasias and hormonal disorders, including patients enrolled into Phase I-III clinical trials. Rotations with non-endocrine specialties such as medical oncology, surgery, pathology and radiology are included.
Research activities will be encouraged with opportunities to present at local, national or international meetings. Academic opportunities will include routine conferences and the education of medical students, residents, or fellows.
How to Apply
- Apply to this program using the DISCOVER online application system
All applicants should have completed a U.S. or Canada-accredited fellowship in endocrinology, diabetes and metabolism or medical oncology in good standing, and must have an active license or be eligible for a license from the Texas Medical Board.
Graduates of foreign medical schools and specialty training programs in endocrinology or medical oncology must have a valid certificate from the Educational Commission for Foreign Medical Graduates (ECFMG) prior to appointment, and must be eligible for an appropriate visa.
Required application materials:
- Completion of an application form
- Personal statement (including goals and reason for pursuing an Oncologic Endocrine Fellowship)
- Curriculum vitae
- Two letters of recommendation, plus one from the fellowship program director
- Medical school transcript
After a review of the application package, a personal interview with faculty members will be arranged with outstanding candidates.
Dr. Luz Castellanos is a board-certified pediatric endocrinologist and the current Oncologic Endocrinology Fellow at MD Anderson Cancer Center in the Department of Endocrine Neoplasia and Hormonal Disorders.
After completing her M.D. at McGovern Medical School, she did her pediatric residency at The University of Texas at Austin Dell Children’s and pediatric endocrinology fellowship at Massachusetts General Hospital. After fellowship, she coupled her clinical practice with clinical trial research on artificial pancreas technologies for diabetes. Dr. Castellanos plans to pursue an academic career specializing in the care of children with cancer-related endocrinopathies and endocrine neoplasia.
MD Anderson Cancer Center is committed to encouraging good health and staying true to our mission to end cancer. If you are applying for a GME fellowship or residency program starting on or after July 1, 2016, please be advised that MD Anderson will have instituted a tobacco-free hiring process as part of its efforts to achieve these goals. If you are offered an appointment, you will be subject to a Pre-Employment Drug Screen for tobacco compounds in compliance with applicable state laws. If you do not pass the urine drug screening which includes testing for tobacco compounds, you CANNOT be appointed at MD Anderson. Should you fail to meet this contingency, MD Anderson will withdraw your offer of appointment for the academic year. You may reapply for the following academic year, but there are no guarantees that you will be offered a position as many of our programs are already filled for several years out.